RedHill Biopharma Successfully Regains Compliance with Nasdaq Stockholders' Equity Requirement

Rhea-AI Summary

RedHill Biopharma (NASDAQ: RDHL) announced it has regained compliance with Nasdaq's stockholders' equity requirement under Listing Rule 5550(b)(1). Nasdaq confirmed compliance on November 26, 2025, restoring the company's conformity with listing standards. The company cited ongoing 2025 strategic initiatives, including the Talicia partnership with Cumberland Pharmaceuticals, and continued focus on operational efficiency. RedHill was advised in the process by Donohoe Advisory.

Positive

• Regained Nasdaq compliance on November 26, 2025

Negative

• None.

News Market Reaction

+3.33%

1 alert

+3.33% News Effect

-5.6% Trough Tracked

+$129K Valuation Impact

$4M Market Cap

0.0x Rel. Volume

On the day this news was published, RDHL gained 3.33%, reflecting a moderate positive market reaction. Argus tracked a trough of -5.6% from its starting point during tracking. This price movement added approximately $129K to the company's valuation, bringing the market cap to $4M at that time.

Data tracked by StockTitan Argus on the day of publication.

Market Reality Check

Price: $1.36 Vol: Volume 21,489 vs 76,019 2...

low vol

$1.36 Last Close

Volume Volume 21,489 vs 76,019 20-day average (relative volume 0.28). low

Technical Price 1.1999 trades below 200-day MA of 1.86, and far under 52-week high 8.37.

Peers on Argus

Among peers, SHPH appeared in momentum scanners, moving up 6.15%, while other tr...

1 Up

Among peers, SHPH appeared in momentum scanners, moving up 6.15%, while other tracked specialty pharma names showed mixed single-digit moves, suggesting today’s setup was more stock-specific than a broad sector trend.

Historical Context

5 past events · Latest: Dec 01 (Positive)

Pattern 5 events

Date	Event	Sentiment	Move	Catalyst
Dec 01	Nasdaq compliance regained	Positive	+3.3%	Nasdaq confirmed stockholders’ equity compliance under Listing Rule 5550(b)(1).
Dec 01	Nasdaq compliance regained	Positive	+3.3%	Nasdaq confirmed stockholders’ equity compliance under Listing Rule 5550(b)(1).
Nov 04	Court judgment win	Positive	-13.4%	New York Supreme Court summary judgment in RedHill’s favor exceeding $10.5M.
Oct 22	Nasdaq non-compliance notice	Negative	-3.3%	Nasdaq staff notification of failure to meet minimum stockholders’ equity.
Oct 20	Talicia co-commercialization	Positive	+15.3%	Cumberland joint venture to commercialize Talicia with shared net revenues.

Pattern Detected

Most company news events saw price moves aligned with the apparent news tone, with one notable divergence on a favorable court judgment.

Recent Company History

Over the last few months, RedHill’s key developments included a co-commercialization deal for Talicia on Oct 20, 2025, a Nasdaq non-compliance notice on Oct 22, 2025, and a New York Supreme Court judgment win reported on Nov 4, 2025. The Talicia deal coincided with a 15.33% gain, while the non-compliance notification and later court victory saw declines of 3.33% and 13.39%. Today’s confirmation of regained Nasdaq equity compliance on Nov 26, 2025 was followed by a modest 3.33% gain, reinforcing the importance of listing status and financial stability to traders.

Market Pulse Summary

This announcement confirmed that RedHill regained compliance with Nasdaq’s stockholders’ equity requ...

Analysis

This announcement confirmed that RedHill regained compliance with Nasdaq’s stockholders’ equity requirement under Listing Rule 5550(b)(1) as of November 26, 2025, removing a prior listing risk flagged in October. It ties into broader 2025 initiatives, including the Talicia partnership and operational efficiency efforts. Investors tracking this name may monitor future equity levels, progress on Talicia commercialization, and any additional regulatory or legal updates disclosed in subsequent filings and press releases.

AI-generated analysis. Not financial advice.

TEL-AVIV, Israel and RALEIGH, N.C., Dec. 1, 2025 /PRNewswire/ -- RedHill Biopharma Ltd. (NASDAQ: RDHL) ("RedHill" or the "Company"), a specialty biopharmaceutical company, today announced that on November 26, 2025, it received confirmation from the Nasdaq Stock Market LLC ("Nasdaq") that the Company has regained compliance with the stockholders' equity requirement set forth in Nasdaq Listing Rule 5550(b)(1)¹.

This achievement aligns with RedHill's ongoing strategic initiatives in 2025, including the Talicia^® partnership with Cumberland Pharmaceuticals and continued focus on operational efficiency.

The Company was advised in this process by Donohoe Advisory.

About RedHill Biopharma    

RedHill Biopharma Ltd. (Nasdaq: RDHL) is a specialty biopharmaceutical company primarily focused on U.S. development and commercialization of drugs for gastrointestinal diseases, infectious diseases and oncology. RedHill promotes the FDA-approved gastrointestinal drug Talicia^®, for the treatment of Helicobacter pylori (H. pylori) infection in adults², with a recent co-commercialization agreement in the U.S. with Cumberland Pharmaceuticals. RedHill's key clinical late-stage development programs include: (i) opaganib (ABC294640), a first-in-class, orally administered sphingosine kinase-2 (SPHK2) selective inhibitor with anti-inflammatory, antiviral, and anticancer activity, targeting multiple indications with U.S. government and academic collaborations for development for radiation and chemical exposure indications such as GI-Acute Radiation Syndrome (GI-ARS), a Phase 2/3 program for hospitalized COVID-19, and a Phase 2 study in prostate cancer in combination with darolutamide; (ii) RHB-204, a next-generation optimized formulation of RHB-104, with a planned Phase 2 study for Crohn's disease (based on RHB-104's positive Phase 3 Crohn's disease study results) and Phase 3-stage for pulmonary nontuberculous mycobacteria (NTM) disease; (iii) RHB-102, with positive results from a U.S. Phase 3 study for acute gastroenteritis and gastritis, positive results from a U.S. Phase 2 study for IBS-D and potential UK submission for chemotherapy and radiotherapy induced nausea and vomiting. RHB-102 is partnered with Hyloris Pharma (EBR: HYL) for worldwide development and commercialization outside North America; and (iv) RHB-107 (upamostat), an oral broad-acting, host-directed, serine protease inhibitor with potential for pandemic preparedness, is in late-stage development as a treatment for non-hospitalized symptomatic COVID-19 and is also targeting multiple other cancer and inflammatory gastrointestinal diseases.

More information about the Company is available at www.redhillbio.com / X.com/RedHillBio.

Forward Looking Statements

This press release contains "forward-looking statements" within the meaning of the Private Securities Litigation Reform Act of 1995 and may discuss investment opportunities, stock analysis, financial performance, investor relations, and market trends. Such statements may be preceded by the words "intends," "may," "will," "plans," "expects," "anticipates," "projects," "predicts," "estimates," "aims," "believes," "hopes," "potential" or similar words. Forward-looking statements include statements based on certain assumptions and are subject to various known and unknown risks and uncertainties, many of which are beyond the Company's control and cannot be predicted or quantified, and consequently, actual results may differ materially from those expressed or implied by such forward-looking statements. Such risks and uncertainties include, without limitation: the risk regarding the Company's ability to maintain compliance with Nasdaq's listing requirements, including  the minimum stockholders' equity requirement; the risk that the strategic transaction with Cumberland will not bring the currently anticipated benefits to RedHill's global Talicia business or to RedHill's financial position, costs or its broader strategic objectives; the risk that the addition of new revenue generating products or out-licensing transactions will not occur; the risk of current uncertainty regarding U.S. government research and development funding and that the U.S. government is under no obligation to continue to support development of our products and can cease such support at any time; the risk that acceptance onto the RNCP Product Development Pipeline or other governmental and non-governmental development programs will not guarantee ongoing development or that any such development will not be completed or successful; the risk that the FDA does not agree with the Company's proposed development plans for its programs; the risk that the Company's development programs and studies may not be successful and, even if successful, such studies and results may not be sufficient for regulatory applications, including emergency use or marketing applications, and that additional studies may be required; the risk that the Company will not successfully commercialize its products; as well as risks and uncertainties associated with (i) the initiation, timing, progress and results of the Company's research, manufacturing, pre-clinical studies, clinical trials, and other therapeutic candidate development efforts, and the timing of the commercial launch of its commercial products and ones it may acquire or develop in the future; (ii) the Company's ability to advance its therapeutic candidates into clinical trials or to successfully complete its pre-clinical studies or clinical trials or the development of any necessary commercial companion diagnostics; (iii) the extent and number and type of additional studies that the Company may be required to conduct and the Company's receipt of regulatory approvals for its therapeutic candidates, and the timing of other regulatory filings, approvals and feedback; (iv) the manufacturing, clinical development, commercialization, and market acceptance of the Company's therapeutic candidates and Talicia; (v) the Company's ability to successfully commercialize and promote Talicia; (vi) the Company's ability to establish and maintain corporate collaborations; (vii) the Company's ability to acquire products approved for marketing in the U.S. that achieve commercial success and build its own marketing and commercialization capabilities; (viii) the interpretation of the properties and characteristics of the Company's therapeutic candidates and the results obtained with its therapeutic candidates in research, pre-clinical studies or clinical trials; (ix) the implementation of the Company's business model, strategic plans for its business and therapeutic candidates; (x) the scope of protection the Company is able to establish and maintain for intellectual property rights covering its therapeutic candidates and its ability to operate its business without infringing the intellectual property rights of others; (xi) parties from whom the Company licenses its intellectual property defaulting in their obligations to the Company; (xii) estimates of the Company's expenses, future revenues, capital requirements and needs for additional financing; (xiii) the effect of patients suffering adverse experiences using investigative drugs under the Company's Expanded Access Program; (xiv) competition from other companies and technologies within the Company's industry; and (xv) the hiring and employment commencement date of executive managers. More detailed information about the Company and the risk factors that may affect the realization of forward-looking statements is set forth in the Company's filings with the Securities and Exchange Commission (SEC), including the Company's Annual Report on Form 20-F filed with the SEC on April 10, 2025. All forward-looking statements included in this press release are made only as of the date of this press release. The Company assumes no obligation to update any written or oral forward-looking statement, whether as a result of new information, future events or otherwise unless required by law. 

Company contact:
Adi Frish
Chief Corporate & Business Development Officer
RedHill Biopharma
+972-54-6543-112
adi@redhillbio.com 

Category: Corporate

¹ To regain compliance with Nasdaq Listing Rule 5550(b)(1), the Company was required to demonstrate that its stockholders' equity exceeded the minimum $2.5 million stockholders' equity requirement and its ability to sustain compliance with such requirement.

² Talicia^® (omeprazole magnesium, amoxicillin and rifabutin) is indicated for the treatment of H. pylori infection in adults. For full prescribing information see: www.Talicia.com.

Logo: https://mma.prnewswire.com/media/1334141/RedHill_Biopharma_Logo.jpg

 

View original content:https://www.prnewswire.com/news-releases/redhill-biopharma-successfully-regains-compliance-with-nasdaq-stockholders-equity-requirement-302629014.html

SOURCE RedHill Biopharma Ltd.

FAQ

When did RedHill Biopharma (RDHL) regain Nasdaq compliance?

Nasdaq confirmed RedHill regained compliance on November 26, 2025.

Which Nasdaq rule did RedHill (RDHL) meet to regain compliance?

RedHill regained compliance with Nasdaq Listing Rule 5550(b)(1) related to stockholders' equity.

Does the RedHill (RDHL) announcement mention partners involved in 2025 strategy?

Yes; the announcement cites the Talicia partnership with Cumberland Pharmaceuticals as a 2025 strategic initiative.

Who advised RedHill (RDHL) during the Nasdaq compliance process?

RedHill was advised by Donohoe Advisory in the compliance process.

Will regaining Nasdaq compliance affect RDHL trading status?

Regaining compliance addresses the stockholders' equity deficiency and restores conformity with Nasdaq listing standards; the announcement confirms compliance as of November 26, 2025.

What operational focus did RedHill (RDHL) highlight in the compliance announcement?

The company highlighted a continued focus on operational efficiency as part of its 2025 initiatives.